LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today announced that Merit Cudkowicz, M.D., will present the scientific data that supports the previously-released conclusions from the Company’s six-month, open-label extension of its Phase IIa clinical trial with arimoclomol in ALS volunteers at the 18th International Symposium on ALS/MND to be held December 1-3, 2007 in Toronto, Canada. Dr. Cudkowicz was a co-principal investigator of the clinical trial. A poster presentation titled “Open Label Extension of Arimoclomol Study AALS-001” will be available Sunday, December 2, 2007.
